Hyperphosphataemia and treatment with sevelamer in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 18, Issue SUPPL. 5, 2003, Pages

  Čižman, Borut ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Calcium phosphate product; Chronic renal failure; Haemodialysis; Hyperphosphataemia; Phosphate binders

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SALT; BILE ACID; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM SALT; COLECALCIFEROL; ERYTHROPOIETIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; POLYMER; SEVELAMER; VITAMIN D DERIVATIVE;

ALUMINUM OVERLOAD; ANEMIA; ARTICLE; ATTENUATION; BIOACCUMULATION; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DEMENTIA; DIALYSATE; DIARRHEA; DIET RESTRICTION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG UTILIZATION; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LONG TERM CARE; METABOLIC ACIDOSIS; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EPOXY COMPOUNDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; POLYETHYLENES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0042812533     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
2. US Renal Data System. 1999 Annual Data Report. The National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 1999
3. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
4. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic hemodialysis patients. Am J Kidney Dis 2000; 27: 394-401
5. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing hemodialysis. N Engl J Med 2000; 342: 1478-1483
6. Wallot M, Bonzel KE, Winter A et al. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 1996; 10: 625-630
7. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
8. Hergesell O, Ritz E. Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant 2002; 17: 14-17
9. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 340-345
10. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701
11. Chertow GM, Dillon MA, Amin N, Burke SK. Sevelamer with and without calcium and vitamin D: observation from a long-term open-label clinical trial. J Ren Nutr 2000; 10: 125-132
12. Chertow GM, Burke SK, Raggi P et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 63: 245-252
13. Chertow GM, Burke SK, Dillon MA et al. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914
14. Goldfarb S. Renal osteodystrophy, disorders of divalent ion metabolism, and nephrolithiasis. NephSAP 2002; 1: 60-68
15. Collins AJ, St Peter WI, Dalleska FW et al. Hospitalization risks between Renagel phosphate binders treated and non-Renagel treated patients. Clin Nephrol 2000; 54: 334-341
16. McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1643-1648